TGFB1 and hepatocellular carcinoma: The non-selective protein kinase inhibitor sorafenib was found to increase DUSP1 expression in the M2 cells of macrophages, resulting in the decreased release of TGF-β and CD206, and, thus, sorafenib better suppresses hepatocellular cancer progression [157].